Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents (CAI:RMDA) PB Ratio: 4.62 (As of Jul. 07, 2026) — 124% Above Median


CAI:RMDA Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents CAI:RMDA
84 GF Score
Price E£5.10
GF Value E£4.08
Valuation Modestly Overvalued
! 9 Warning Signs
View Full Analysis

What is Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents PB Ratio?

Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents CAI:RMDA +1.80% 84 PB Ratio is 4.62 as of Jul. 07, 2026, which is 124% above its 10-year median of 2.06. GuruFocus rates CAI:RMDA with a GF Score™ of 84/100 and a GF Value™ of E£4.08 (Modestly Overvalued). The stock has 9 warning signs investors should review. Among 921 Drug Manufacturers companies, Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents ranks worse than 79.26% on this metric.

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-07), Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's share price is E£5.10. Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's Book Value per Share for the quarter that ended in Mar. 2026 was E£1.11. Hence, Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's PB Ratio of today is 4.62.

Warning Sign:

Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents stock PB Ratio (=4.53) is close to 10-year high of 4.64.

The historical rank and industry rank for Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's PB Ratio or its related term are showing as below:

CAI:RMDA' s PB Ratio Range Over the Past 10 Years
Min: 1.22   Med: 2.06   Max: 4.64
Current: 4.61

During the past 8 years, Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's highest PB Ratio was 4.64. The lowest was 1.22. And the median was 2.06.

CAI:RMDA's PB Ratio is ranked worse than
79.26% of 921 companies
in the Drug Manufacturers industry
Industry Median: 1.93 vs CAI:RMDA: 4.61

During the past 12 months, Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's average Book Value Per Share Growth Rate was 3.40% per year. During the past 3 years, the average Book Value Per Share Growth Rate was 11.80% per year. During the past 5 years, the average Book Value Per Share Growth Rate was 13.70% per year.

During the past 8 years, the highest 3-Year average Book Value Per Share Growth Rate of Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents was 41.90% per year. The lowest was 11.80% per year. And the median was 14.90% per year.

Back to Basics: PB Ratio


Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents  (CAI:RMDA) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents PB Ratio Related Terms


Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents PB Ratio Historical Data

* Premium members only.

The historical data trend for Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents PB Ratio Chart

Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PB Ratio
Get a 7-Day Free Trial 1.78 1.90 1.40 2.46 3.07

Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.11 3.32 3.02 3.07 3.67

CAI:RMDA vs ZTS, UTHR, VTRS: PB Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's PB Ratio distribution charts can be found below:

* The bar in red indicates where Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's PB Ratio falls into.


CAI:RMDA
84GF Score
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents CAI:RMDA
PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Mar. 2026)
=5.10/1.105
=4.62

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.

Frequently Asked Questions Learn more about PB Ratio →
What does a PB Ratio of 4.62 mean?
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents (CAI:RMDA) has a PB Ratio of 4.62 as of Jul. 07, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents and its competitors. This is 124% above median its historical median of 2.06. Over the past decade, Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents' PB Ratio has ranged from 1.22 to 4.64. According to the industry distribution chart, Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents ranks #730 out of 921 companies in the Drug Manufacturers industry, placing it in the top 79.3%.
Is Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents' PB Ratio too high?
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents' current PB Ratio of 4.62 is 124% above median its 10-year median of 2.06. Over the past 10 years, this metric has ranged from a low of 1.22 to a high of 4.64. The Drug Manufacturers industry median PB Ratio is 1.93. Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents' value of 4.62 is 139.4% above this industry median. Based on the distribution chart, Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents ranks #730 out of 921 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents has a GF Score™ of 84/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents' PB Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents ranks #730 out of 921 companies for PB Ratio. This places Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents in the lower half of its industry. The industry median PB Ratio is 1.93. Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents' value of 4.62 is 139.4% above this benchmark. Historically, Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents' own PB Ratio has ranged from 1.22 to 4.64 over the past decade. While the company's 10-year median is 2.06 vs. the industry median of 1.93, Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.93, based on 921 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's current PB Ratio of 4.62 is 139.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's current PB Ratio is 4.62, which is 124% above median its own 10-year median of 2.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents stock overvalued right now?
Based on GuruFocus' analysis, Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents (CAI:RMDA) is currently considered Modestly Overvalued. The stock's GF Value™ is E£4.08, compared to a current price of E£5.10 — trading 25% above its estimated fair value. The current PB Ratio is 4.62, which is 124% above median its 10-year median of 2.06 and 139.4% above the Drug Manufacturers industry median of 1.93. Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents' overall GF Score™ is 84/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents (CAI:RMDA), the current PB Ratio is 4.62 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents (CAI:RMDA) Overvalued in 2026?

Based on GuruFocus' analysis, Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents stock appears to be overvalued. The current stock price of E£5.10 is trading 25% above its estimated GF Value™ of E£4.08. GuruFocus considers Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents to be Modestly Overvalued.

Key valuation signals for CAI:RMDA:

  • PB Ratio: 4.62 (124% above median its 10-year median of 2.06)
  • GF Value™: E£4.08 vs. price of E£5.10 (25% above fair value)
  • GF Score™: 84/100 with 9 warning signs
  • Industry Position: 139.4% above the Drug Manufacturers median (#730 of 921)

No single metric tells the full story. See the CAI:RMDA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents Business Description

Address No. 5 Second Industrial Zone, Sixth of October City, Giza, EGY
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents is a pharmaceutical company. The company is engaged in the Manufacturing, marketing, selling and storing of pharmaceutical reagents for human and veterinary use; manufacturing, marketing, selling and storing of diagnostic reagents necessary for individuals, laboratories and hospitals; importing pharmaceutical reagents and raw materials necessary for serving the its purposes without trading; producing pharmaceutical reagents for human and veterinary and diagnostic use for others and by others; and producing food supplements for human use for others and by others. It has two segments: production and selling of pharmaceutical products, which generates maximum revenue; and manufacturing for others (Toll manufacturing).
84GF Score

Get the complete analysis for CAI:RMDA

PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

E£5.10
Price
E£4.08
GF Value